Steve Connor: The results so far arec good, but there's still a long way to go before an effective malaria vaccine is available
Steve Connor is the Science Editor of The Independent. He has won many awards for his journalism, including five-times winner of the prestigious British science writers’ award; the David Perlman Award of the American Geophysical Union; twice commended as specialist journalist of the year in the UK Press Awards; UK health journalist of the year and a special merit award of the European School of Oncology for his investigative journalism. He has a degree in zoology from the University of Oxford and has a special interest in genetics and medical science, human evolution and origins, climate change and the environment.
Tuesday 08 October 2013
The vaccine known as "RTS,S", made by GlaxoSmithKline, was the first "candidate" vaccine against malaria and was initially developed as long ago as 1987. This fact alone indicates just how difficult and tortuous it is to manufacture a safe, reliable and effective vaccine against the malaria parasite.
Malaria is caused by a relatively sophisticated single-celled microbe, Plasmodium falciparum, with a complex life-cycle. The parasite can change its outer protein coat to confuse the body's immune defences and so effectively presents a constantly moving target for the vaccine "bullet".
In addition, the Plasmodium parasite can hide within the blood cells of the body, making it virtually unrecognisable to the immune defences that a vaccine stimulates. The microbe also flips from one stage of its life-cycle to another and infects more than one set of tissues in the body.
Nevertheless, RTS,S is the first malaria candidate vaccine - and there have been many over the decades - to reach the stage of widespread testing at the most advanced phase of clinical trials. It is designed to prevent the Plasmodium parasite from infecting, maturing and multiplying in the liver, from where the parasite will re-enter the bloodstream to infect red blood cells and so cause symptoms.
The vaccine is supposed to work by stimulating both arms of the immune system, the free-floating antibodies - the specialised proteins of the immune defences - and the killer T-cells of the blood which are designed to seek out and destroy alien invaders.
This phase III study, based on 15,000 immunised children, is now at the 18-month stage following vaccination. The results are impressive, with nearly 50 per cent protection, which although not brilliant will be good enough to make a big difference in fighting a disease that still kills more than 600,000 people a year - most of them children.
However, this trial still has some way to go before it concludes. The efficacy of the vaccine for infants and young children could well go down further still - it was higher at the 12-month stage - which would raise serious questions about its usefulness.
Further findings from the 32-month stage of follow-up, and the impact of a booster given after 18 months, will be made available next year. We should know then whether we really do have an effective vaccine against malaria.
- 1 'Not suppost to cry': 9-year-old lists the worst things about being a boy
- 2 Lee Evans announces his retirement from comedy on The Jonathan Ross Show
- 3 Iggy Azalea responds to Eminem rape lyrics: 'I'm bored of old men threatening young women'
- 4 These grandmas smoking weed for the first time are wonderful
- 5 Pastafarian former porn star Asia Lemmon allowed to wear colander in driving licence photo
Duchess of Alba dead: Billionaire Spanish duchess who lived life by her own rules, dies at 88
New York snowstorm: Death toll rises to 10 as residents battle with further snowfall
These grandmas smoking weed for the first time are wonderful
Chelsea balcony collapse: Two people dead and six injured in London
Woman opens professional cuddling shop – gets 10,000 customers in first week
Rochester by-election: Ukip gains second MP as Tory defector Mark Reckless holds seat
'Muslims pre-date Columbus in discovering America,' says Turkish president Erdogan
Rochester by-election: Labour MP Emily Thornberry resigns after posting white van and England flags tweet
France 'blocks' Russian sailors from boarding a warship
Former Tory PM Sir John Major says 'we would not have an NHS without migrants'
Revealed: How the world gets rich – from privatising British public services
£8 - £12 per hour: Recruitment Genius: To assist a young family with the care ...
£20000 per annum: Recruitment Genius: A Customer Service Executive is required...
£55000 - £70000 per annum: Argyll Scott International: My client, a world lead...
Negotiable: Argyll Scott International: My client, a world leading services pr...